Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 91

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 4
Chunk 91
---
 studies and clinical trials, and our research and development programs;

●
the timing of anticipated regulatory filings;

●
the timing of availability of data from our clinical trials;

●
our future expenses, capital requirements, need for additional financing, and the period over which we believe that the net proceeds
from this offering, together with our existing cash and cash equivalents, will be sufficient to fund our operating expenses and capital
expenditure requirements;

●
our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals;

● our ability to advance product candidates into, and successfully complete, clinical trials;

●
our ability to recruit and enroll suitable patients in our clinical trials;

●
the timing or likelihood of the accomplishment of various scientific, clinical, regulatory, and other product development objectives;

●
the pricing and reimbursement of our product candidates, if approved;

●
the rate and degree of market acceptance of our product candidates, if approved;

●
the implementation of our business model and strategic plans for our business, product candidates, and technology;

●
the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;

●
developments relating to our competitors and our industry; and

●
other risks and factors listed under “Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December
31, 2024.

Given
the risks and uncertainties set forth in this quarterly report, you are cautioned not to place undue reliance on such forward-looking
statements. The forward-looking statements contained in this quarterly report are not guarantees of future performance and our actual
results of operations, financial condition, and liquidity, and the development of the industry in which we operate, may differ materially
from the forward-looking statements contained in this quarterly report. In addition, even if our results of operations, financial condition
and liquidity, and events in the industry in which we operate are consistent with the forward-looking statements contained in this quarterly
report, they may not be predictive of results or developments in future periods.

Any
forward-looking statement that we make in this quarterly report speaks only as of the date of such statement. Except as required by federal
securities laws, we do not undertake any obligation to update or revise, or to publicly announce any update or revision to, any of the
forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this quarterly report.

20

PART